Medical Daily

Novartis Multiple Sclerosis Drug, Gilenya, Implicated In Rare Brain Disease; FDA Continues To Investigate

Roseland Community Hospital will stop delivering babies on Oct. 31, adding to South Side maternity closures. Its OB clinic will stay open. LA County issued an extreme heat warning for Oct. 2 to 8, ...
Healthline

Gilenya (Fingolimod) Cost and Financial Assistance

The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost of ...
Healthline

Side Effects of Gilenya: What You Need to Know

Gilenya may also be prescribed to treat clinically isolated syndrome (CIS). People with CIS often (but not always) develop MS later on. If you and your doctor agree that Gilenya is working well for ...
FiercePharma

Novartis' Gilenya patent loss sets MS market up for battle with early generics

Novartis lost an appeal to protect a 2026 patent on multiple sclerosis blockbuster Gilenya, which brought in more than $3 billion last year. Novartis' bid to fend off early Gilenya generics has failed ...
Yahoo Finance

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

Basel, May 11, 2018 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years ...
Yahoo Finance

New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years

The digital press release with multimedia content can be accessed here: Basel, September 16, 2016 - Novartis today announced new data from the ACROSS study, which assessed 10-year disability outcomes ...
irblog.prnewswire.com

Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC

EAST HANOVER, N.J., May 30, 2013 /PRNewswire/ -- People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya ® (fingolimod) vs.
FiercePharma

Riding on patent office win, Novartis takes Gilenya generics fight to court

Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to use that win in court ...
irblog.prnewswire.com

Novartis Therapy Gilenya™ Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows

EAST HANOVER, N.J., April 11, 2011 /PRNewswire/ -- A new analysis demonstrated that Gilenya™ (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple ...
Pharmabiz

Novartis confirms Gilenya exhibits safety in trials; reduces rate of brain volume loss

Novartis has confirmed the latest global patient-use data which showed that Gilenya (fingolimod) has been used to treat more than 63,000 patients in clinical trials and the post-marketing setting.
JD Supra

PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation

In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not unpatentable on three separate grounds. Shortly thereafter, ...